Patents by Inventor Fabio E. S. Souza

Fabio E. S. Souza has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 10662178
    Abstract: The present invention provides a novel crystalline form of Olaparib comprising Olaparib and benzyl alcohol, compositions thereof, and the use of this crystalline form in the treatment of cancers, such as germline BRCA-mutated (gBRCAm) advanced ovarian cancer.
    Type: Grant
    Filed: January 30, 2019
    Date of Patent: May 26, 2020
    Assignee: Apotex Inc.
    Inventors: Allan W. Rey, Fabio E. S. Souza, Annyt Bhattacharyya, Bahareh Khalili
  • Patent number: 10632107
    Abstract: The present invention provides crystalline forms of Deutetrabenazine. Specific crystalline forms provided by the present invention include Deutetrabenazine Form APO-I, a co-crystal of Deutetrabenazine and quercetin, and Deutetrabenazine Form APO-II, a co-crystal of Deutetrabenazine and luteolin. Also provided are pharmaceutical compositions including the Deutetrabenazine crystalline forms, and the use of these forms in the treatment of tardive dyskinesia and chorea associated with Huntington's disease.
    Type: Grant
    Filed: May 13, 2019
    Date of Patent: April 28, 2020
    Assignee: Apotex Inc.
    Inventors: Fabio E. S. Souza, Bahareh Khalili, Allan W. Rey
  • Patent number: 10611772
    Abstract: The present invention provides a novel crystalline form of Ribociclib succinate, Ribociclib succinate Form APO-I, including Ribociclib succinate, benzyl alcohol and water, compositions thereof, processes for the preparation thereof, and the use of this crystalline form in the treatment of conditions associated with increased CDK4/6 kinase activity, and in particular, cancers, including certain forms of breast cancer.
    Type: Grant
    Filed: June 27, 2019
    Date of Patent: April 7, 2020
    Assignee: Apotex Inc.
    Inventors: Fabio E. S. Souza, Bahareh Khalili
  • Publication number: 20200095255
    Abstract: The present invention provides novel crystalline forms of Ponatinib hydrochloride. Specific crystalline forms provided by the present invention include Ponatinib hydrochloride Form APO-I, APO-III and APO-IV, each of which is obtained from acetonitrile/formic acid solutions. Additionally, Form APO-V is provided, which is obtained from concentrated hydrochloric acid.
    Type: Application
    Filed: June 15, 2018
    Publication date: March 26, 2020
    Inventors: Fabio E. S. Souza, Bahareh Khalili, Katherine A. Rantanen, Jenny L. Gerster, Annyt Bhattacharyya, Boris Gorin, Allan W. Rey
  • Publication number: 20200079740
    Abstract: The present invention provides a novel crystalline form of Eluxadoline, Eluxadoline Form APO-I, a co-crystal of Eluxadoline and methyl nicotinate, compositions and processes for the preparation thereof, and the use of this crystalline form in the treatment of opioid-modulated disorders, and in particular, gastrointestinal disorders, including irritable bowel syndrome with diarrhea (IBS-D).
    Type: Application
    Filed: November 14, 2019
    Publication date: March 12, 2020
    Inventors: Fabio E. S. Souza, Bahareh Khalili, Annyt Bhattacharyya
  • Publication number: 20200002343
    Abstract: The present invention provides a novel crystalline form of Ribociclib succinate, Ribociclib succinate Form APO-I, including Ribociclib succinate, benzyl alcohol and water, compositions thereof, processes for the preparation thereof, and the use of this crystalline form in the treatment of conditions associated with increased CDK4/6 kinase activity, and in particular, cancers, including certain forms of breast cancer.
    Type: Application
    Filed: June 27, 2019
    Publication date: January 2, 2020
    Inventors: Fabio E. S. Souza, Bahareh Khalili
  • Publication number: 20190390235
    Abstract: The present invention provides processes for the preparation of Dasotraline, as well as intermediates useful in the preparation thereof. In particular, processes are provided for the enzymatic transamination of a compound of Formula (2) to afford Dasotraline.
    Type: Application
    Filed: June 12, 2019
    Publication date: December 26, 2019
    Inventors: Fabio E. S. Souza, Prabhudas Bodhuri, Eduardo Gustavo Cammisa, Gamini Weeratunga, Allan W. Rey
  • Patent number: 10513504
    Abstract: The present invention provides processes for the preparation of Apalutamide (1), as well as intermediates useful in the preparation thereof. In particular, the process of the invention utilizes the intermediate compound of Formula (2), wherein G is OH or a leaving group, which provides improvements over the known processes for the preparation of Apalutamide (1).
    Type: Grant
    Filed: March 6, 2019
    Date of Patent: December 24, 2019
    Assignee: Apotex Inc.
    Inventors: Prabhudas Bodhuri, Alfredo Paul Ceccarelli, Michael R. Emmett, Avedis Karadeolian, Fabio E. S. Souza, Gamini Weeratunga, Boris Gorin
  • Patent number: 10487059
    Abstract: The present invention provides a novel crystalline form of Eluxadoline, Eluxadoline Form APO-I, a co-crystal of Eluxadoline and methyl nicotinate, compositions and processes for the preparation thereof, and the use of this crystalline form in the treatment of opioid-modulated disorders, and in particular, gastrointestinal disorders, including irritable bowel syndrome with diarrhea (IBS-D).
    Type: Grant
    Filed: September 24, 2018
    Date of Patent: November 26, 2019
    Assignee: Apotex Inc.
    Inventors: Fabio E. S. Souza, Bahareh Khalili, Annyt Bhattacharyya
  • Publication number: 20190343815
    Abstract: The present invention provides crystalline forms of Deutetrabenazine. Specific crystalline forms provided by the present invention include Deutetrabenazine Form APO-I, a co-crystal of Deutetrabenazine and quercetin, and Deutetrabenazine Form APO-II, a co-crystal of Deutetrabenazine and luteolin. Also provided are pharmaceutical compositions including the Deutetrabenazine crystalline forms, and the use of these forms in the treatment of tardive dyskinesia and chorea associated with Huntington's disease.
    Type: Application
    Filed: May 13, 2019
    Publication date: November 14, 2019
    Inventors: Fabio E.S. Souza, Bahareh Khalili, Allan W. Rey
  • Publication number: 20190276424
    Abstract: The present invention provides processes for the preparation of Apalutamide (1), as well as intermediates useful in the preparation thereof. In particular, the process of the invention utilizes the intermediate compound of Formula (2), wherein G is OH or a leaving group, which provides improvements over the known processes for the preparation of Apalutamide (1).
    Type: Application
    Filed: March 6, 2019
    Publication date: September 12, 2019
    Inventors: Prabhudas Bodhuri, Alfredo Paul Ceccarelli, Michael R. Emmett, Avedis Karadeolian, Fabio E. S. Souza, Gamini Weeratunga, Boris Gorin
  • Patent number: 10407396
    Abstract: The present invention provides a novel crystalline form of Selexipag, Selexipag Form APO-I, which is a methanol solvate of Selexipag, compositions thereof, and the use of this crystalline form in the treatment of pulmonary arterial hypertension.
    Type: Grant
    Filed: November 9, 2018
    Date of Patent: September 10, 2019
    Assignee: Apotex Inc.
    Inventors: Fabio E. S. Souza, Bahareh Khalili, Katherine A. Rantanen, Annyt Bhattacharyya, Jenny L. Gerster, Allan W. Rey
  • Publication number: 20190233400
    Abstract: The present invention provides a novel crystalline form of Olaparib comprising Olaparib and benzyl alcohol, compositions thereof, and the use of this crystalline form in the treatment of cancers, such as germline BRCA-mutated (gBRCAm) advanced ovarian cancer.
    Type: Application
    Filed: January 30, 2019
    Publication date: August 1, 2019
    Inventors: Allan W. Rey, Fabio E. S. Souza, Annyt Bhattacharyya, Bahareh Khalili
  • Patent number: 10301274
    Abstract: Disclosed are salts of a compound of formula 1, as shown below, where R1, R2, R3, R4? R5, R6 and R7 are as described herein. Also, disclosed is a process for the preparation of the salts of the compounds of formula 1, and intermediates used therein. The salts of the compound of formula 1 can be useful for preparation of halichondrin analogs such as eribulin.
    Type: Grant
    Filed: March 6, 2015
    Date of Patent: May 28, 2019
    Assignee: Sandoz AG
    Inventors: Fabio E. s. Souza, Ricardo Orprecio, Ming Pan
  • Publication number: 20190144397
    Abstract: The present invention provides a novel crystalline form of Selexipag, Selexipag Form APO-I, which is a methanol solvate of Selexipag, compositions thereof, and the use of this crystalline form in the treatment of pulmonary arterial hypertension.
    Type: Application
    Filed: November 9, 2018
    Publication date: May 16, 2019
    Inventors: Fabio E. S. Souza, Bahareh Khalili, Katherine A. Rantanen, Annyt Bhattacharyya, Jenny L. Gerster, Allan W. Rey
  • Publication number: 20190112299
    Abstract: The present invention provides a novel crystalline form of Lumacaftor, specifically Lumacaftor Form APO-1, a co-crystal of Lumacaftor and nicotinamide, compositions including this crystalline form, and processes for the preparation of this crystalline form.
    Type: Application
    Filed: October 15, 2018
    Publication date: April 18, 2019
    Inventors: Fabio E. S. Souza, Bahareh Khalili, Katherine A. Rantanen
  • Publication number: 20190092734
    Abstract: The present invention provides a novel crystalline form of Eluxadoline, Eluxadoline Form APO-I, a co-crystal of Eluxadoline and methyl nicotinate, compositions and processes for the preparation thereof, and the use of this crystalline form in the treatment of opioid-modulated disorders, and in particular, gastrointestinal disorders, including irritable bowel syndrome with diarrhea (IBS-D).
    Type: Application
    Filed: September 24, 2018
    Publication date: March 28, 2019
    Inventors: Fabio E. S. Souza, Bahareh Khalili, Annyt Bhattacharyya
  • Patent number: 10183024
    Abstract: The present invention provides crystalline forms of Ibrutinib. Specific crystalline forms provided by the present invention include Ibrutinib Form APO-I, an anhydrous form; APO-II, a methyl benzoate solvate of Ibrutinib; and APO-IV, a methyl salicylate solvate of Ibrutinib.
    Type: Grant
    Filed: November 30, 2017
    Date of Patent: January 22, 2019
    Assignee: Apotex Inc.
    Inventors: Fabio E. S. Souza, Annyt Bhattacharyya, Bahareh Khalili, Allan W. Rey, Boris Gorin
  • Publication number: 20180153895
    Abstract: The present invention provides crystalline forms of Ibrutinib. Specific crystalline forms provided by the present invention include Ibrutinib Form APO-I, an anhydrous form; APO-II, a methyl benzoate solvate of Ibrutinib; and APO-IV, a methyl salicylate solvate of Ibrutinib.
    Type: Application
    Filed: November 30, 2017
    Publication date: June 7, 2018
    Inventors: Fabio E. S. Souza, Annyt Bhattacharyya, Bahareh Khalili, Allan W. Rey, Boris Gorin
  • Patent number: 9850254
    Abstract: Disclosed is a compound of formula 1, or a pharmaceutically acceptable salt thereof, where R1, R2, R3, R4, R5, R6, R7, R7?, R8, R9, R10, R11, R12 and R13 are as disclosed herein. Also, disclosed is a process for the preparation of the compound of formula 1, or a pharmaceutically acceptable salt thereof, and intermediates used therein. The compound of formula 1 can be used in the preparation of halichondrin analogs, such as Eribulin; and a process for its preparation from the compound of formula 1 is also disclosed.
    Type: Grant
    Filed: May 30, 2014
    Date of Patent: December 26, 2017
    Assignee: Sandoz AG
    Inventors: Fabio E. S. Souza, Alena Rudolph, Dino Alberico, Robert Jordan, Ming Pan, Boris Gorin